Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438303 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT05438303 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 59 participants.
The verdict
NCT05438303, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
This study will be a fixed sequence drug-drug interaction study in healthy postmenopausal females, conducted at multiple study sites
Interventions
- DRUG Midazolam
- DRUG Celecoxib
- DRUG Omeprazole
- DRUG AZD9833
- DRUG Dabigatran Etexilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2022-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05438303
The ClinicalTrials.gov registry entry for NCT05438303 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT05438303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05438303 about?
NCT05438303 is a clinical study titled "Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers". This study will be a fixed sequence drug-drug interaction study in healthy postmenopausal females, conducted at multiple study sites
What is the current status of trial NCT05438303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2022-06-13. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT05438303?
The interventions under investigation include: Midazolam (DRUG), Celecoxib (DRUG), Omeprazole (DRUG), AZD9833 (DRUG), Dabigatran Etexilate (DRUG).
Who is sponsoring clinical trial NCT05438303?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.